© 2021 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Drug Pipeline
2021 Starts Off Strong — and Controversial
July 12, 2021
Not in recent memory has an FDA approval stirred up so much controversy as the agency’s OK of Aduhelm, Biogen’s Alzheimer’s treatment.
2021 Managed Healthcare Executive® Pharmacy Survey: Drugs New to the Market Most Likely to Reduce Morbidity, Mortality
June 16, 2021
In this part five series, participants give their opinions on which drugs newer to the market in the last 12 months hold the most promise to reducing morbidity and mortality. Participants also shared which drug in the pipeline holds the most promise. MHE's annual pharmacy survey had over 225 respondents. We will be posting the results over the next few days.
Will Gene Therapy Change the Treatment of Muscular Dystrophy?
June 08, 2021
The jury is still out. Several companies have high hopes for candidates under development.
New Hemophilia Treatments Look to Cut Number of Infusions
May 12, 2021
Longer half-lives mean less frequent administration and improved quality of life.
ICER Says Alzheimer's Drug Aducanumab Should Be Priced at Between $2,560-$8,290
May 06, 2021
The Institute for Clinical and Economic Review's price range is far below the $50,000 per year envisioned by some market analysts.
Is Inclisiran a PCSK9 Inhibitor?
April 16, 2021
In this third part of a three-part series, Steven D. Pearson, M.D., M.Sc., founder and president of ICER talks the drug Inclisiran and its relation to PCSK9 inhibitors.
Migraine Treatment Awash in Choices
April 15, 2021
The triptans, long the workhorses of migraine treatment, have been joined by monoclonal antibodies and small-molecule drugs that block calcitonin gene-related peptide. What’s lacking is a precision approach to treatment based on biomarkers.
The COVID-19 vaccine race was a sprint. Now for the hurdles
March 08, 2021
Will emerging variants make the leading vaccines less protective?
The Search for new COPD Therapies
February 09, 2021
The COPD Foundation is calling for a change in clinical trial design that would test experimental therapies in subsets of patients.
COVID-19 Response in Japan, Sweden and the United States
February 01, 2021
Opinion piece by MHE's Editorial Advisory Board Member and CEO of The Pharmacy Group, Perry Cohen. Perry discusses the response differences and vague similarities between the countries and addresses the continuous question, "What is the new normal?"